Your session is about to expire
← Back to Search
Nivolumab Combination Therapy for Colorectal Cancer (CheckMate142 Trial)
CheckMate142 Trial Summary
This trial will test if Nivolumab can effectively treat colon cancer that has returned or spread, specifically in patients whose tumors have a certain biomarker.
CheckMate142 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate142 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CheckMate142 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or can carry out light work.I have previously been treated with drugs targeting immune system checkpoints.I haven't taken steroids or immunosuppressants in the last 14 days.I do not have cancer that has spread to my brain or its coverings.You have a condition where your immune system attacks your own body and it is currently active or suspected to be active.I have not had any cancer, except for treatable local cancers, in the last 3 years.My cancer shows microsatellite instability.My colorectal cancer has returned or spread to other parts.
- Group 1: Nivolumab + Ipilimumab + Cobimetinib Cohort C4
- Group 2: Nivolumab Monotherapy
- Group 3: Nivolumab + Ipilimumab
- Group 4: Nivolumab + Ipilimumab Cohort C3
- Group 5: Nivolumab + Daratumumab Cohort C6
- Group 6: Nivolumab + BMS-986016 Cohort C5
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What health concerns does Nivolumab treatment address?
"Nivolumab is conventionally employed to manage unamenable melanoma, as well as squamous cell carcinoma and hematopoietic stem-cell transplants which have not responded to a previous treatment."
Are there any regional sites hosting this clinical research?
"Presently, this trial has 34 separate locations available for enrollment; some of the most common cities are Minneapolis, Portland and Atlanta. To reduce travel strains it would be beneficial to select a site nearby you."
Has the FDA greenlit Nivolumab for use in medical treatments?
"According to our assessment, the safety rating of Nivolumab is a 2. This drug has some evidence showcasing its security but no data yet validating its efficacy."
How many participants are currently enrolled in this medical research project?
"This study has already concluded its recruitment phase, the last update to their trial occurring on October 26th 2022. If you are currently looking for other trials related to colorectal carcinoma and Nivolumab respectively, there are 864 and 949 studies that still need participants."
Are there vacancies for participants in this experiment?
"This research endeavour is not currently accepting participants. The trial was first uploaded on 12th March 2014 and edited most recently on 26th October 2022. Other available studies include 864 trials searching for patients with colorectal carcinoma, as well as 949 trials that are actively recruiting those who need Nivolumab treatment."
Are there any published reports of research conducted using Nivolumab?
"At the moment, 949 investigations of Nivolumab are still in progress and 115 have reached Phase 3. While a few studies centered around this drug take place in Pittsburgh, Pennsylvania, there is an array of 49386 locations conducting research on it."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger